Cancer Organoid

Breast Cancer Organoid

Breast cancer organoids are three-dimensional (3D) models that closely replicate the structure and cellular composition of actual cancer tissue.
By preserving key characteristics of breast cancer, including genetic mutations and protein expression patterns, these organoids serve as reliable models for cancer research.
Their ability to maintain tumor heterogeneity and accurately mimic the tumor microenvironment (TME) makes them invaluable for studying disease progression and treatment responses.
As physiologically relevant models, breast cancer organoids play a crucial role in advancing precision medicine and facilitating the development of more effective cancer therapies.


Price	1784€+ Login to see price
Organism	Human
Product Type	Organoid, Tissue derived organoid
Tissue	Breast
Disease	Breast cancer

Applications

Toxicity

Small molecules

mRNA

Antibody

Cancer vaccine

Immune Cells

Immuno Oncology with TME

Cytotoxic T cell

TIL (Tumor infiltrating lymphocytes)

Regulatory T cell

Macrophage

CAF (Cancer associate fibroblast)

Description

Cellular and structural similarity

Our breast cancer organoids exhibit a high degree of pathological similarity to patient-derived tumor tissues, expressing key breast cancer markers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).

Immunohistochemistry (IHC) analyses confirm that these markers are expressed in the organoids in patterns consistent with those observed in primary tumors, accurately reflecting the differentiation status and histological characteristics of the original tissue.

These pathological marker analyses demonstrate that breast cancer organoids faithfully recapitulate the morphological and molecular features of patient tumors, establishing them as a reliable platform for cancer pathology research, drug development, and the evaluation of personalized therapeutic strategies.

Drug sensitivity testing for Precision Oncology

A tailored solution for evaluating the efficacy and resistance of new drugs is available using an established breast cancer (BC) organoid library.

By leveraging comprehensive drug sensitivity data, the most suitable organoid lines are selected based on the characteristics of the investigational drug, enabling precise and reliable drug testing.

Drug sensitivity tests have been conducted using Carboplatin, Cisplatin and Paclitaxel which are widely used in clinical cancer treatment, and drug response data from a subset of BC organoid models has been collected. This dataset continues to expand as additional testing is performed.

This organoid-based drug sensitivity testing platform enhances the efficiency and reliability of the drug development process and contributes to the advancement of personalized cancer treatment strategies.